UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial
Sandip M. Prasad·Mark Schoenberg·Nikola V. Mihaylov·Pencho Genov·Vasyl Terzi·Max Kates·William C. Huang·Michael J. Louie·Brent Burger·Andrew Meads·Dimitar Shishkov
Patients who achieved CR following UGN-102 treatment had a high probability of remaining event-free 24 months later. These data indicate UGN-102 is a novel, nonsurgical treatment that provides a durable CR for patients with recurrent LG-IR-NMIBC. Study limitations included the single-arm design and the limited racial diversity of the patients.